Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 156 for:    bimatoprost
Previous Study | Return to List | Next Study

A Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04285580
Recruitment Status : Active, not recruiting
First Posted : February 26, 2020
Last Update Posted : June 29, 2021
Sponsor:
Information provided by (Responsible Party):
Allergan

Brief Summary:
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

Condition or disease Intervention/treatment Phase
Open-Angle Glaucoma Ocular Hypertension Drug: Bimatoprost SR Drug: LUMIGAN Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
Actual Study Start Date : June 11, 2020
Estimated Primary Completion Date : August 11, 2021
Estimated Study Completion Date : May 15, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
Drug Information available for: Bimatoprost

Arm Intervention/treatment
Experimental: Bimatoprost SR 10 μg
Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
Drug: Bimatoprost SR
Consists of 1 Bimatoprost SR administration in the study eye.

LUMIGAN 0.01%
Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
Drug: LUMIGAN
Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.




Primary Outcome Measures :
  1. Change from Baseline in Time-Matched Intraocular Pressure (IOP) for Bimatoprost SR treated eyes [ Time Frame: 8 weeks ]
    IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

  2. Number of patients experiencing one or more treatment emergent adverse events (TEAEs) [ Time Frame: Up to 12 months ]
    The number of patients who experienced one or more TEAEs


Secondary Outcome Measures :
  1. Change from Baseline in range of IOP for Bimatoprost SR-treated eyes [ Time Frame: 8 Weeks ]
    IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment
  • Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months

Exclusion Criteria:

  • Current or anticipated enrollment in another investigational drug or device study
  • Females who are pregnant, nursing, or planning a pregnancy during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04285580


Locations
Layout table for location information
United States, Alabama
Trinity Research Group /ID# 232749
Dothan, Alabama, United States, 36301
United States, California
Eye Research Foundation /ID# 232694
Newport Beach, California, United States, 92663
United States, Georgia
Coastal Research Associates /ID# 232798
Roswell, Georgia, United States, 30076
United States, North Carolina
James D Branch MD /ID# 232718
Winston-Salem, North Carolina, United States, 27101
United States, Pennsylvania
Scott and Christie and Associates /ID# 232747
Cranberry Township, Pennsylvania, United States, 16066
United States, Texas
Keystone Research LTD /ID# 232665
Austin, Texas, United States, 78731-4203
Sponsors and Collaborators
Allergan
Investigators
Layout table for investigator information
Study Director: ALLERGAN INC. Allergan
Additional Information:
Layout table for additonal information
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT04285580    
Other Study ID Numbers: 1698-304-007
First Posted: February 26, 2020    Key Record Dates
Last Update Posted: June 29, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: For details on when studies are available for sharing, please refer to the link below
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
URL: https://vivli.org/ourmember/abbvie/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Bimatoprost
Antihypertensive Agents